ThinkSabio

$JNJ

$266.50▲ +0.1% YTD

18 SEC 13D/G filings tracked · Last updated Oct 27, 2026

Filing History
News
JNJ ▲ +0.1% - Johnson & Johnson
CP $266.50▲ +0.1%Oct 27, 2026 · ThinkSabio Blog

$JNJ - Johnson & Johnson to Host Enterprise Business Review…

News
JNJ ▼ -1.4% - Johnson & Johnson
CP $263.81▲ -1.4%Oct 25, 2026 · ThinkSabio Blog

$JNJ - RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients w…

News
JNJ ▼ -1.4% - Johnson & Johnson
CP $263.81▲ -1.4%Oct 25, 2026 · ThinkSabio Blog

$JNJ - Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule…

News
JNJ ▲ +1.0% - Johnson & Johnson
CP $260.22▲ +1.0%Oct 22, 2026 · ThinkSabio Blog

$JNJ Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment…

News
JNJ ▼ -0.7% - Johnson & Johnson
CP $257.63▲ -0.7%Oct 21, 2026 · ThinkSabio Blog

$JNJ d/g Hold @ Erste…

News
JNJ ▲ +0.8% - Johnson & Johnson
CP $255.88▲ +0.8%Oct 20, 2026 · ThinkSabio Blog

$JNJ Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half…

News
JNJ ▼ -0.8% - Johnson & Johnson
CP $253.48▲ -0.8%Oct 19, 2026 · ThinkSabio Blog

$JNJ JOHNSON & JOHNSON ANNOUNCES NEW DATA SHOWING TREMFYA® (GUSELKUMAB) IS THE ONLY IL-23 TO DELIVER DURABLE FISTULA REMISSION THROUGH 48 WEEKS IN CRO…

News
JNJ ▼ -0.7% - Johnson & Johnson
CP $262.06▲ -0.7%Oct 13, 2026 · ThinkSabio Blog

$JNJ - Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026…

News
JNJ ▲ +0.9% - Johnson & Johnson
CP $263.73▲ +0.9%Oct 12, 2026 · ThinkSabio Blog

$JNJ - New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups…

News
JNJ ▲ +0.9% - Johnson & Johnson
CP $263.73▲ +0.9%Oct 12, 2026 · ThinkSabio Blog

$JNJ - TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease…

News
JNJ ▲ +0.5% - Johnson & Johnson
CP $260.15▲ +0.5%Oct 2, 2026 · ThinkSabio Blog

$JNJ Johnson & Johnson: Phase 3 ICONIC-TOTAL Two-Year ICOTYDE Data Show High Complete Clearance Rates at Difficult Psoriasis Sites ? • At Week 112, 60…

News
JNJ ▲ +0.5% - Johnson & Johnson
CP $260.15▲ +0.5%Oct 2, 2026 · ThinkSabio Blog

$JNJ - Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affi…

News
JNJ ▼ -0.0% - Johnson & Johnson
CP $272.02▲ -0.0%Sep 29, 2026 · ThinkSabio Blog

$JNJ - Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu)…

News
JNJ ▲ +0.1% - Johnson & Johnson
CP $271.28▲ +0.1%Sep 25, 2026 · ThinkSabio Blog

$JNJ - Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stif…

News
JNJ ▲ +0.1% - Johnson & Johnson
CP $271.28▲ +0.1%Sep 25, 2026 · ThinkSabio Blog

$JNJ J&J - FIVE-YEAR OVERALL SURVIVAL RATE 69.2%, MEDIAN PROGRESSION-FREE SURVIVAL 60.5 MONTHS…

News
JNJ ▲ +0.3% - Johnson & Johnson
CP $270.15▲ +0.3%Sep 23, 2026 · ThinkSabio Blog

$JNJ - New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fi…

News
JNJ ▲ +0.4% - Johnson & Johnson
CP $266.71▲ +0.4%Sep 15, 2026 · ThinkSabio Blog

$JNJ - RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-re…

News
JNJ ▼ -1.6% - Johnson & Johnson
CP $270.62▲ -1.6%Sep 8, 2026 · ThinkSabio Blog

$JNJ - Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026…